---
title: "Ocumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273006067.md"
description: "Ocumension Therapeutics has completed enrollment of 195 patients in a real-world study of OT-703 (ILUVIEN) for diabetic macular edema in Hainan, China. The implant, approved by the U.S. FDA, offers a three-year sustained-release profile. This study aims to generate local evidence for potential commercialization in Greater China and other Asian markets, though success is not guaranteed. The latest analyst rating for Ocumension (HK:1477) is a Hold with a price target of HK$7.50. The company focuses on developing treatments for eye diseases in the region."
datetime: "2026-01-19T22:42:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273006067.md)
  - [en](https://longbridge.com/en/news/273006067.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273006067.md)
---

# Ocumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Ocumension Therapeutics ( (HK:1477) ) just unveiled an announcement.

Ocumension Therapeutics has completed enrollment of 195 patients in a real-world study of OT-703 (ILUVIEN), a fluocinolone acetonide intravitreal implant for diabetic macular edema, at the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, China. The implant, already approved by the U.S. FDA and registered in Hong Kong, is the only corticosteroid intraocular implant with a three-year sustained-release profile for DME, and the Hainan study marks a key step in generating local real-world evidence to support its regional rollout and potential commercialization across Greater China and other Asian markets, although the company cautions that successful commercialization is not assured.

The most recent analyst rating on (HK:1477) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

**More about Ocumension Therapeutics**

Ocumension Therapeutics is an ophthalmic-focused biopharmaceutical company specializing in the development and commercialization of treatments for eye diseases in Greater China and selected Asian markets. Through licensing agreements, such as its exclusive deal with Alimera Sciences for ILUVIEN, the company is building a portfolio targeting conditions like diabetic macular edema, with a strategic focus on bringing advanced international ophthalmic therapies into the region.

**Average Trading Volume:** 1,075,277

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$6.1B

### Related Stocks

- [01477.HK](https://longbridge.com/en/quote/01477.HK.md)

## Related News & Research

- [Clarity Medical Group’s Business Rebounds as It Works Toward Trading Resumption](https://longbridge.com/en/news/282706799.md)
- [10:52 ETSinocare Showcases Digital Innovation at the 93rd CMEF, Advancing Global Chronic Disease Management](https://longbridge.com/en/news/282420735.md)
- [At ASCRS/ASOA 2026, the Saffron Solution Exposes the Hidden Operational Leaks Costing Ophthalmology Practices Growth, Access, and Revenue](https://longbridge.com/en/news/281929390.md)
- [10:03 ETPara celebrar el hito de 100.000 pacientes tratados, Nordic Pharma Inc. (EE.UU.) amplía su oferta](https://longbridge.com/en/news/282210909.md)
- [Viatris Ophthalmology Data At ASCRS Puts Valuation And Dividend In Focus](https://longbridge.com/en/news/282750345.md)